Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guidant (GDT) -- Ignore unavailable to you. Want to Upgrade?

To: Lighthouse who wrote (209)	9/4/2002 11:32:18 AM
From: Ausdauer	Respond to of 235

Lighthouse, I think it is difficult to know with certainty how things will play out. The market will be better for consumers if there is a choice of manufacturers and I hope that there are a variety of coated stents available and at a reasonable cost to the health care system. Only time will tell what preferences will be expressed and what degree of market acceptance and penetration will occur. If the coated stents are as good as billed in the hands of the average physician then this will be a revolutionary treatment. I think it will be difficult to predict physician practices and don't presume to know the eventual outcome of the battle between parties driving this revolution. Aus

To: Lighthouse who wrote (209)	9/4/2002 10:18:01 PM
From: Ausdauer	Respond to of 235

Lighthouse, I imagine BSX has spent a ton on clinical research to date. If their legal dispute with GDT over ANPI's licensing agreement with BSX and Cook goes unfavorably I don't think they are going to have to be taken down kicking. I think it has the potential to get real ugly. You can imagine that part of their interest in funding such trials was the expectation that their would be some licensing exclusivity. It is going to get ugly. Aus

To: Lighthouse who wrote (209)	10/2/2002 11:58:49 AM
From: Ausdauer	Respond to of 235

"GDT is making a big investment in Cook in order to try to level the playing field. At the current stock price of GDT a $3 billion dollar investment translates to about 80 million new GDT shares, a greater than 25% dilution in outstanding shares. That is a big price to pay for technology that is second to market. If the deal falls through and GDT has no drug-eluting stents to compete with JNJ it is easy to predict that it will lose substantial market share in this book of business, and quite rapidly." Message 17949433 I think it was a no-win situation for GDT and today's market action reflects that. Boston Scientific spent millions on research in good faith expecting the previously negotiated licenses to come through. GDT's tactics were executed, IMHO, in desperation. Message 17954318 Aus (GDT intraday low $24.75)